Slavica BioChem scientists reverse multidrug resistance in lung cancer using small molecules

Using small molecules (purine analogs) scientists managed to reverse multidrug resistance in lung cancer, a common obstacle to successful cancer chemotherapy.

HTDS www.htdsmedical.com (HTDS) - The issuer's Serbia based operating subsidiary Slavica BioChem www.slavicabiochem.com brings attention to its Mindup Bioresearch cancer project working on molecular origins of lung cancer: prospects for personalized prevention and therapy. On October 8 2009, the company posted a filing on Pink Sheets titled MindUp Cancer Project.

The company is using this opportunity to shed some light the significance of that filing. The MindUp group focused their investigation on inactivation of tumour suppressors as molecular marker events highly related to the pathogenesis of non-small cell lung carcinoma (NSCLC). To that end, they use paired tumour and normal lung tissue samples and blood obtained from patients with NSCLC after surgery. These results are presented at AACR (American Association for Cancer Research) Conference, Frontiers in Basic Cancer Research, http://www.aacr.org/home/scientists/meetings--workshops/frontiers-in-cancer-prevention-research.aspx October 8 - 11, 2009. Boston, Massachusetts, on poster entitled "The impact of inactivation of p53 and PTEN tumor suppressors on promotion and progression of human non-small cell lung carcinoma" (authors: Tijana Andjelkovic, Jasna Bankovic, Vedrana Milinkovic, Ana Podolski, Sabera Ru dijic, Nikola Tanic).

For example a recent article (see Globe and Mail Newspaper unauthorized link: http://www.theglobeandmail.com/news/national/canadians-uncover-the-cancer-map/article1316312/ ) reports that a team of British Columbia based scientists decodes the metastatic breast-cancer genome, shedding light on how tumours develop by understanding their mutations. The landmark achievement opens up a world of new ways to fight the disease - including personalized treatments.

MindUp cancer project scientists are of the opinion that their work is further advanced then the aforementioned, because their research led to the identification of genes associated with lung cancer promotion and progression, that may be potential biomarkers and useful for personalized therapy. Using small molecules (purine analogs) they managed to reverse multidrug resistance in lung cancer, a common obstacle to successful cancer chemotherapy.

As per the news release of yesterday Oct 13 2009 and a Filing of October 1 2009 Titled "Shareholders FAQ on Mellow Hope Slavica and HTDS"s MindUp cancer project and its planned split off. The company sees this as a significant event for its MindUp cancer project, and brings attention to that filing.

Progress on the MindUp will be reported back at earliest by next week.